Effects of sulphydryl- and non-sulphydryl-containing ACE inhibitors on left ventricular relaxation in the isolated guinea pig heart.
ACE inhibitors exert both acute and chronic beneficial effects on cardiac function (e.g remodelling, diastolic dysfunction). We have previously reported that the ACE inhibitor captopril induces selective left ventricular (LV) relaxant effects in the isolated ejecting guinea pig heart. The aim of the present study was to further investigate the mechanism of the captopril-induced changes in early LV relaxation by comparing the effects of two sulphydryl and two non-sulphydryl containing ACE inhibitors in the same experimental preparation. Isolated ejecting guinea pig hearts were studied under conditions of constant loading and heart rate. LV pressure was monitored by a 2F micromanometer-tipped catheter transducer inserted in the LV cavity. The sulphydryl-containing ACE inhibitors captopril and zofenaprilat enhanced early LV relaxation, whereas the non-sulphydryl-containing ACE inhibitors lisinopril and quinaprilat did not. The effects of captopril and zofenaprilat were attenuated both by the nitric oxide-scavenger haemoglobin and the bradykinin B2-kinin receptor antagonist HOE 140. Neither the oxygen free-radical scavenger superoxide dismutase nor the sulphydryl-containing compound N-acetyl cysteine administered together with lisinopril had any effect on LV relaxation. These data demonstrate that inhibition of intra-cardiac ACE activity may acutely modulate LV relaxation through increased activity of the bradykinin-nitric oxide pathway. The presence of a sulphydryl group on the relevant ACE inhibitor appears to be essential for this LV relaxant effect.
Anning
P B
PB
Department of Pharmacology & Therapeutics, University of Wales College of Medicine, Heath Park, Cardiff, United Kingdom.
Grocott-Mason
R M
RM
Lewis
M J
MJ
D000111:Acetylcysteine / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000737:chemistry / Q000145:classification / Q000494:pharmacology*; D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology; D065168:Bradykinin Receptor Antagonists; D002216:Captopril / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D003971:Diastole / Q000187:drug effects; D005260:Female; D016166:Free Radical Scavengers / Q000494:pharmacology; D006168:Guinea Pigs; D006352:Heart Ventricles / Q000187:drug effects*; D006454:Hemoglobins / Q000494:pharmacology; D007546:Isoquinolines / Q000737:chemistry / Q000494:pharmacology*; D017706:Lisinopril / Q000737:chemistry / Q000494:pharmacology*; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects; D009569:Nitric Oxide / Q000502:physiology; D043782:Receptor, Bradykinin B2; D012841:Simethicone / Q000494:pharmacology; D013318:Stroke Volume / Q000187:drug effects*; D013438:Sulfhydryl Compounds / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000494:pharmacology; D013599:Systole / Q000187:drug effects; D044005:Tetrahydroisoquinolines; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000503:physiopathology
D000806:Angiotensin-Converting Enzyme Inhibitors; D065168:Bradykinin Receptor Antagonists; D016166:Free Radical Scavengers; D006454:Hemoglobins; D007546:Isoquinolines; D043782:Receptor, Bradykinin B2; D013438:Sulfhydryl Compounds; D044005:Tetrahydroisoquinolines; C044958:zofenopril; D009569:Nitric Oxide; C054501:quinaprilat; C065679:icatibant; D012841:Simethicone; D002216:Captopril; D017706:Lisinopril; D013482:Superoxide Dismutase; D001920:Bradykinin; D000111:Acetylcysteine